Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
2mg Baricitinib
China SXT Pharmaceuticals
Acute Ichemic Stroke
1 trial -
BARICITINIB, ADALIMUMAB, ADALIMUMAB, Baricitinib, BARICITINIB, BARICITINIB
Eli Lilly Co.
Uveitis
1 trial -
BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib
Eli Lilly Co.
Diabetes Mellitus, Type 1
1 trial -
BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB
Eli Lilly Co.
Juvenile Idiopathic Arthritis
1 trial -
BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB
Eli Lilly Co.
Diabetes Mellitus, Type 1
1 trial -
BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension
Eli Lilly Co.
Atopic Dermatitis
1 trial -
Baricitinib
Eli Lilly Co.
Covid19 Corona Virus Infection
1 trial -
Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg
Pari Pharma GmbH
Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.
1 trial -
TOCILIZUMAB, MOXIFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN LACTOBIONATE, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTRIAXONE, BARICITINIB, HYDROCORTISONE, DEXAMETHASONE, ROXITHROMYCIN, LEVOFLOXACIN, BALOXAVIR MARBOXIL, AZITHROMYCIN, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , AZITHROMYCIN, IMATINIB, OSELTAMIVIR, CLARITHROMYCIN, DEXAMETHASONE, ERYTHROMYCIN
Disc Medicine
Respiratory tract infection
1 trial -
Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB
Eli Lilly Co.
Systemic Juvenile Idiopathic Arthritis
1 trial -
BARICITINIB
Pari Pharma GmbH
Juvenile Dermatomyositis
1 trial -
Baricitinib 2 MG [Olumiant]
China SXT Pharmaceuticals
Immune Thrombocytopenia
1 trial -
INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM
Pari Pharma GmbH
Sepsis
1 trial -
ADALIMUMAB, BARICITINIB, BARICITINIB, ADALIMUMAB, ETANERCEPT
Eli Lilly Co.
Rheumatoid Arthritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources